TruBridge Valuation

Is TBRG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TBRG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TBRG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TBRG's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TBRG?

Other financial metrics that can be useful for relative valuation.

TBRG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1x
Enterprise Value/EBITDA44.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TBRG's PS Ratio compare to its peers?

The above table shows the PS ratio for TBRG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
OPRX OptimizeRx
1.7x19.4%US$143.5m
AMWL American Well
0.6x12.2%US$136.0m
TRHC Tabula Rasa HealthCare
0.8x13.2%US$284.0m
SOPH SOPHiA GENETICS
3.4x15.2%US$214.5m
TBRG TruBridge
0.5x4.4%US$169.9m

Price-To-Sales vs Peers: TBRG is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (1.9x).


Price to Earnings Ratio vs Industry

How does TBRG's PE Ratio compare vs other companies in the US Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: TBRG is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Healthcare Services industry average (2.3x).


Price to Sales Ratio vs Fair Ratio

What is TBRG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TBRG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: TBRG is good value based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TBRG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.88
US$12.20
+2.7%
12.0%US$14.00US$10.00n/a5
Sep ’25US$12.47
US$12.20
-2.2%
12.0%US$14.00US$10.00n/a5
Aug ’25US$10.82
US$13.80
+27.5%
37.6%US$24.00US$10.00n/a5
Jul ’25US$10.57
US$13.80
+30.6%
37.6%US$24.00US$10.00n/a5
Jun ’25US$9.41
US$13.80
+46.7%
37.6%US$24.00US$10.00n/a5
May ’25US$8.06
US$14.00
+73.7%
36.4%US$24.00US$10.00n/a5
Apr ’25US$8.42
US$14.00
+66.3%
36.4%US$24.00US$10.00n/a5
Mar ’25US$9.19
US$14.25
+55.1%
39.8%US$24.00US$10.00n/a4
Feb ’25US$10.24
US$16.50
+61.1%
31.3%US$24.00US$10.00n/a4
Jan ’25US$11.20
US$18.67
+66.7%
22.0%US$24.00US$14.00n/a3
Dec ’24US$10.86
US$18.67
+71.9%
22.0%US$24.00US$14.00n/a3
Nov ’24US$14.17
US$25.33
+78.8%
7.4%US$28.00US$24.00n/a3
Oct ’24US$15.94
US$25.33
+58.9%
7.4%US$28.00US$24.00US$11.903
Sep ’24US$16.25
US$27.25
+67.7%
13.6%US$33.00US$24.00US$12.474
Aug ’24US$26.28
US$27.67
+5.3%
13.6%US$33.00US$25.00US$10.823
Jul ’24US$24.69
US$27.67
+12.1%
13.6%US$33.00US$25.00US$10.573
Jun ’24US$24.54
US$27.67
+12.7%
13.6%US$33.00US$25.00US$9.413
May ’24US$26.76
US$35.67
+33.3%
12.6%US$41.00US$30.00US$8.063
Apr ’24US$30.20
US$38.50
+27.5%
6.5%US$41.00US$36.00US$8.422
Mar ’24US$29.91
US$38.50
+28.7%
6.5%US$41.00US$36.00US$9.192
Feb ’24US$29.66
US$38.50
+29.8%
1.3%US$39.00US$38.00US$10.242
Jan ’24US$27.22
US$38.50
+41.4%
1.3%US$39.00US$38.00US$11.202
Dec ’23US$29.28
US$38.50
+31.5%
1.3%US$39.00US$38.00US$10.862
Nov ’23US$32.08
US$40.00
+24.7%
5.0%US$42.00US$38.00US$14.172
Oct ’23US$27.88
US$40.00
+43.5%
5.0%US$42.00US$38.00US$15.942

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies